Table 1.
Clinical trials with pharmacologic treatments for smoking cessation.
| Author | Name of drug | Type | Phase | Result |
|---|---|---|---|---|
| Yammine L | Exenatide | GLP-1 receptor agonist | I/II | Recruiting |
| Mckee SA | Guanfacine | Alpha-2 adrenergic agonist | II | Active, not recruiting |
| Anderson D | Lorcaserin hydrochloride |
Selective 5-HT (2C) agonist | II | Lorcaserin (10 mg, b.i.d.), 15.31%; Lorcaserin (10 mg, q.d.), 8.72%; placebo, 5.64% |
| Castro M | Nadolol | Nonselective beta-blocker | II | Nadolol, 61.6%; placebo, 50% |
| Hill KP | D-cycloserine | Partial NMDA-agonist | I/II | D-cycloserine, 2.57 ± 3.63 cigarettes/day; placebo, 0.29 ± 0.25 cigarettes/day |
| Gyaw S | AZD8529 | Positive allosteric modulator at the mGluR2 receptor | II | AZD8529 (low dose), 9.6%; AZD8529 (high dose), 10.0% |
| Fava M | GSK598809 | D3 antagonist | II | GSK598809, 0%; placebo, 0% |
| Ashare RL | Liraglutide | Long-acting analogue of human GLP | II | Recruiting |
| Davis JM | AXS-05 | 5-HT2A receptor antagonist | II | Active, not recruiting |
| Mckee SA | Doxazosin | Selective antagonist at postsynaptic α1-adrenergic receptors | II | Doxazosin (8 mg), 27.557 ± 6.409 (stress) and 23.776 ± 7.192 (neutral); doxazosin (4 mg) 32.128 ± 7.494 (stress) and 26.790 ± 8.410 (neutral); placebo, 11.304 ± 7.407 (stress) and 23.474 ± 8.312 (neutral) |
GLP, glucagon-like peptide; HT, hydroxytryptamine; mGluR, metabotropic glutamate receptor; NMDA, N-methyl-d-aspartate.